SCHEMBL5310940

SCHEMBL5310940

COC(=O)c1ccc(CN(C)CCCN(C)CC(=O)Nc2ccc(OCCc3ccccc3)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 16/20 0.66
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPT P10636 1/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312545 0.93 LTA4H (0.77) LTA4H
SCHEMBL5312752 0.92 LTA4H (0.56) LTA4HKDM4EALDH1A1MAPT
SCHEMBL5385123 0.88 LTA4H (0.54) LTA4HKDM4EALDH1A1MAPT
SCHEMBL5312334 0.88 LTA4H (0.85) LTA4H
SCHEMBL5657997 0.85 MAPT (0.50) LTA4HKDM4EALDH1A1MAPTMEN1
SCHEMBL5333739 0.83 LTA4H (0.80) LTA4H
SCHEMBL3040571 0.81 MEN1 (0.63) LTA4HMEN1KMT2A
SCHEMBL5659966 0.80 LTA4H (1.00) LTA4H
SCHEMBL5317924 0.79 LTA4H (1.00) LTA4H
SCHEMBL5313201 0.79 LTA4H (0.77) LTA4HKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007079003-A2 AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-07-12 WO claimed
WO-2007079003-A2 AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-07-12 WO disclosed
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase SCHERING AKTIENGESSELLSCHAFT (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S LTA4H 1/4885KDM4E 1019/4885ALDH1A1 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.